NovaBiotics announces first patients dosed in Lynovex clinical study

Aberdeen based company NovaBiotics Ltd, which is backed by Woodford Investment Management and a number of Scottish Business Angels, has announced the first patients have been dosed in Lynovex clinical study.

NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.

To see a full press release please click HERE.